Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead's Investigational Antiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19

Business Wire May 1, 2020

Gilead Sciences Announces Second Quarter 2020 Dividend

Business Wire April 30, 2020

Gilead Sciences Announces First Quarter 2020 Financial Results

Business Wire April 30, 2020

Dow Sprouts Wings on Positive Gilead News

Livemoney April 29, 2020

Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19

Business Wire April 29, 2020

Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases' Study of Investigational Antiviral Remdesivir for COVID-19

Business Wire April 29, 2020

As Pandemic Progresses, Promising Projects Thrive or Fail in Rally for Effective Coronavirus Treatment

Livemoney April 28, 2020

Futures Hike Friday

Livemoney April 24, 2020

Stocks Close Flat Amid Wild Session

Livemoney April 23, 2020

Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells

Business Wire April 21, 2020

Rally in Store for Markets on Hope of COVID Drug Effectiveness

Livemoney April 17, 2020

Gilead Sciences to Release First Quarter 2020 Financial Results on Thursday, April 30, 2020

Business Wire April 16, 2020

Gilead Provides Additional Information Regarding 2020 Annual Meeting of Stockholders Due to COVID-19 Precautions

Business Wire April 15, 2020

Data on 53 Patients Treated With Investigational Antiviral Remdesivir Through the Compassionate Use Program Published in New England Journal of Medicine

Business Wire April 10, 2020

Gilead Canada Submits Supplemental New Drug Submission to Health Canada for DESCOVY® for HIV Pre-Exposure Prophylaxis

Canada NewsWire April 9, 2020

Gilead Announces $20 Million Philanthropic Fund to Support Nonprofit Organizations Impacted by the COVID-19 Crisis

Business Wire April 8, 2020

Gilead Completes Acquisition of Forty Seven, Inc.

Business Wire April 7, 2020

Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery

Business Wire April 6, 2020

Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma

Business Wire April 2, 2020

Gilead Announces Expiration of Hart-Scott-Rodino Waiting Period for Forty Seven Tender Offer

Business Wire March 30, 2020